HIV-1 biological phenotype and predicted coreceptor usage based on V3 loop sequence in paired PBMC and plasma samples

Virus Res. 2007 Dec;130(1-2):34-42. doi: 10.1016/j.virusres.2007.05.011. Epub 2007 Jun 19.

Abstract

Paired PBMCs and plasma samples from 34 HIV-infected patients were studied to verify the relationship between coreceptor use based on genotyping of V3 region of HIV-1 envelope gp120 and biological phenotype with virus isolation and subsequent correlation to clinical characteristics. The "11/25" rule, geno2pheno and PSSM were compared. All SI patients were HIV-1 subtype B (p=0.04) and had a lower CD4 count than NSI patients (p=0.01), while no differences were observed in mean HIV-RNA (log) (p=0.6). SI phenotype was not associated with AIDS-defining events (p=0.1) or with concurrent antiretroviral therapy (p=0.4). With geno2pheno, which shows the highest sensibility (83%), an X4 or X4/R5 genotype in PBMC DNA was also associated to B-subtype and lower CD4 count (p=0.01) compared to R5 isolates. Based on plasma RNA sequences, the predicted coreceptor usage agreed with PBMC DNA in 79% of cases with the "11/25" rule, 82% with geno2pheno, and 82% with PSSM. A X4 virus in plasma (but not in PBMCs) was significantly associated with HAART in all three methods (p=0.01 for "11/25" rule, p=0.01 for geno2pheno and p=0.03 for PSSM). Due to viral mixtures and/or difficulties in genotype interpretation, current V3 sequence-based methods cannot accurately predict HIV-1 coreceptor use.

MeSH terms

  • CD4 Lymphocyte Count
  • Giant Cells / virology*
  • HIV Envelope Protein gp120 / chemistry
  • HIV Envelope Protein gp120 / genetics
  • HIV Envelope Protein gp120 / physiology*
  • HIV Infections / virology*
  • HIV-1 / genetics
  • HIV-1 / isolation & purification
  • HIV-1 / physiology*
  • Humans
  • Leukocytes, Mononuclear / virology*
  • Molecular Sequence Data
  • RNA, Viral / blood
  • Sequence Analysis, DNA
  • Virus Attachment*

Substances

  • HIV Envelope Protein gp120
  • RNA, Viral
  • gp120 protein, Human immunodeficiency virus 1

Associated data

  • GENBANK/DQ984217
  • GENBANK/DQ984218
  • GENBANK/DQ984219
  • GENBANK/DQ984220
  • GENBANK/DQ984221
  • GENBANK/DQ984222
  • GENBANK/DQ984223
  • GENBANK/DQ984224
  • GENBANK/DQ984225
  • GENBANK/DQ984226
  • GENBANK/DQ984227
  • GENBANK/DQ984228
  • GENBANK/DQ984229
  • GENBANK/DQ984230
  • GENBANK/DQ984231
  • GENBANK/DQ984232
  • GENBANK/DQ984233
  • GENBANK/DQ984234
  • GENBANK/DQ984235
  • GENBANK/DQ984236
  • GENBANK/DQ984237
  • GENBANK/DQ984238
  • GENBANK/DQ984239
  • GENBANK/DQ984240
  • GENBANK/DQ984241
  • GENBANK/DQ984242
  • GENBANK/DQ984243
  • GENBANK/DQ984244
  • GENBANK/DQ984245
  • GENBANK/DQ984246
  • GENBANK/DQ984247
  • GENBANK/DQ984248
  • GENBANK/DQ984249
  • GENBANK/DQ984250
  • GENBANK/DQ984251
  • GENBANK/DQ984252
  • GENBANK/DQ984253
  • GENBANK/DQ984254
  • GENBANK/DQ984255
  • GENBANK/DQ984256
  • GENBANK/DQ984257
  • GENBANK/DQ984258
  • GENBANK/DQ984259
  • GENBANK/DQ984260
  • GENBANK/DQ984261
  • GENBANK/DQ984262
  • GENBANK/DQ984263
  • GENBANK/DQ984264
  • GENBANK/DQ984265
  • GENBANK/DQ984266
  • GENBANK/DQ984267
  • GENBANK/DQ984268
  • GENBANK/DQ984269
  • GENBANK/DQ984270
  • GENBANK/DQ984271
  • GENBANK/DQ984272
  • GENBANK/DQ984273
  • GENBANK/DQ984274
  • GENBANK/DQ984275
  • GENBANK/DQ984276